Back to Sectors

MXCT

MAXCYTE, INC.
2 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

BULLISH | 70% | 5/13/2026 | margin expansionBEARISH | 60% | 5/13/2026 | earnings missBULLISH | 50% | 5/13/2026 | guidance raiseBULLISH | 70% | 5/13/2026 | margin expansionBEARISH | 60% | 5/13/2026 | earnings missBULLISH | 50% | 5/13/2026 | guidance raiseMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bullishMay 13

Net loss reduced by over 50% YoY due to aggressive operating expense cuts.

margin expansion
70%
bearishMay 13

Core revenue declined 25% year-over-year, signaling weakness in product demand.

earnings miss
60%
bullishMay 13

Non-core milestone and royalty revenue surged 60% as partners hit clinical targets.

guidance raise
50%
bullishMay 13

Net loss reduced by over 50% YoY due to aggressive operating expense cuts.

margin expansion
70%
bearishMay 13

Core revenue declined 25% year-over-year, signaling weakness in product demand.

earnings miss
60%
bullishMay 13

Non-core milestone and royalty revenue surged 60% as partners hit clinical targets.

guidance raise
50%

Filing History

10-QMay 13, 2026

The Q1 2026 filing presents a company at a critical crossroads, balancing a leaner cost structure against a declining core revenue base. While the dramatic reduction in operating losses and the surge in milestone payments provide a temporary lifeline, the underlying trend in product sales remains a point of concern for long-term sustainability. Investors are essentially weighing the reliability of MaxCyte's SPL partnerships against the volatility of the cell therapy market. The company's ability to maintain its 12-month runway without further dilution will depend on whether the recent launch of the ExPERT DTx can reverse the slide in core revenue or if the high-margin milestone payments can offset the persistent operating cash burn.